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ABSTRACT
In Japan, the vast majority of females between 13 and 24 are now unvaccinated for HPV and thus 
unprotected from HPV-caused cervical cancer. We analyzed the differences among these unvaccinated 
females regarding their understanding of the HPV vaccine, its role in cervical cancer prevention, and their 
need for cervical cancer screening – based on whether they refused vaccination when their government’s 
recommendation for HPV vaccination was still in effect (vaccination-recommended group) – or during the 
last 7 years, while the government suspension was in effect (recommendation-suspended group). The 
vaccination-recommended group understood more about the HPV vaccine and the best timing for HPV 
vaccination than the recommendation-suspended group (p < .0001 and p = .002, respectively). We found 
that girls in the vaccination-recommended group had more chances to talk with the family about cervical 
cancer and they were more afraid of acquiring the disease (p < .0001 and p < .0001, respectively). The girls 
in the recommendation-suspended group tended to feel more inhibited from talking about cervical cancer 
with friends and acquaintances (p = .0262). The cervical cancer screening rate of the vaccination- 
recommended group was significantly higher (p = .014).
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The vast majority of cervical cancers are caused by one of the 
several oncogenic strains of the human papillomavirus 
(HPV),1,2 thus HPV vaccines are expected to be one of the 
two powerful preventive tools against cervical cancer; the other 
being routine cervical cancer screening. In other countries, 
HPV vaccination is trusted and recommended for all girls. In 
the United States it is recommended for all girls 9–12 years of 
age, in Australia girls 12–13 years of age, and in Canada girls 
11–14 years of age.3 On the other hand, trial with the quad-
rivalent vaccine had shown efficacy against infection and dis-
ease in men who had sex with women and/or men preventing 
HPV 16 and 11 genital warts and HPV 6, 11, 16 and 18 anal 
intraepithelial neoplasia in 2011. Based on the result, HPV 
vaccination was recommended for boys in the U.S. from 
2011, in Australia from 2013, in Canada from 2017.4,5 The 
gender-neural HPV vaccination is recommended in 33 coun-
tries now.6
Japan’s own national HPV vaccination program began in 
2010. By April of 2013, the scheduling of HPV vaccination for 
girls aged 12–16 had become part of its national routine. 
However, in June 2013, a small number of highly publicized 
reports that alleged adverse medical events, such as chronic 
pain and motor impairment, had occurred in several young 
girls following their HPV immunization. The Japanese 
Ministry of Health, Labor, and Welfare (MHLW) almost 
immediately suspended its previous official recommendation 
for HPV vaccination.7 As a consequence, the vaccination rate 
in Japan plummeted, from approximately 70% the year before 
(2012), to 1% or less that year, where the rate still resides today, 
seven years later.8 There has recently been a trend for increas-
ing cervical cancer rates at ever younger ages, potentially linked 
to this ongoing lapse in vaccination protection.
Cervical cancer screening is yet another powerful pre-
ventive measure against cervical cancer. However, the cer-
vical cancer screening rate in Japanese females, at less than 
40% of all eligible women, is unusually low relative to 
similarly advanced countries. Most notably, the cervical 
screening rate among Japanese women in their early twen-
ties is only 10%.9
We report here on the differences we found in young 
HPV-unvaccinated Japanese women regarding their under-
standing of HPV vaccine, cervical cancer and cervical cancer 
screening – that was linked to whether they were teenagers 
during the government’s pro-HPV vaccination recommenda-
tion period or during the later recommendation-suspension 
period.
Methods
From March 19 to 21 of 2020, under Internal Review Board 
approval, we conducted an online survey of Japanese 
18–19 year-old girls who were members of an internet survey 
panel. These girls made up the recommendation-suspended 
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group. Informed consent was obtained from all participants 
and their mothers.
Valid survey answers were obtained from 184 girls. They are 
all HPV-unvaccinated at the time of our survey. A self- 
administered questionnaire was given. The girls were asked 
about their understanding regarding cervical cancer and HPV 
vaccination and whether or not they were having cervical 
cancer screenings. They were asked about their family’s socio- 
demographic characteristics, such as employment and civil 
status, and total household income. Questions also probed 
their knowledge concerning the HPV vaccine, about the best 
timing for vaccination or having a cervical cancer screening, 
about having talks with family about cervical cancer, and 
whether they worried about being affected with cervical cancer.
For comparison of our current results in those of women 
who grew of age during the golden period of pro-vaccination 
policies, we pulled up the results of an internet survey we had 
conducted in February 2015 of unvaccinated girls in the vacci-
nation-recommended group. That survey had been conducted 
among 16 ~ 39 year-old women and investigated their thinking 
about cervical cancer prevention. We extracted the responses 
of 251 unvaccinated 18–19 year-old girls from the self- 
administered questionnaire for those questions which were 
the same as in the most recent questionnaire we gave to the 
recommendation-suspended group. We evaluated for differ-
ences in understandings about the HPV vaccine and cervical 
cancer, and about rates of cervical cancer screening between 
the vaccination-recommended group and the recommendation- 
suspended group of unvaccinated females.
Statistics
Using StatsModels, differences between the two groups were 
calculated by the chi-square test and the logistic regression test 
for categorical variables. The level of statistical significance was 
set at p = .05.
Results
Characteristics of the survey responders
The relevant characteristics of the responders are shown in 
Table 1. Women in the vaccination-recommended group were 
much more likely to be married (p = .0021), and were more 
likely to be stay-at-home wives (p = .0049) (Table 1).
Awareness regarding the HPV vaccine
In reference to the question of awareness of the HPV vaccine, 
98.8% (248/251) of the vaccination-recommended group knew 
about the HPV vaccine, whereas in the recommendation- 
suspended group, only 60.3% (111/184) knew about the vaccine 
(Table 2). In reference to the question regarding recognition 
that the best timing for HPV vaccination was before having her 
first sexual relationship, in the vaccination-recommended 
group, 18.7% knew the fact well, 13.1% knew it a little bit, 
and 68.2% did not know the fact. In the recommendation- 
suspended group, 7.1% knew the fact well, 16.3% knew a little, 
and 76.6% did not know this fact (Table 2). In reference to the 
question of recognition of the cervical cancer preventative 
effects of the HPV vaccine, we found no significant differences 
in the answers from the girls in the two groups (Table 2).
Understanding of cervical cancer
We questioned the women regarding several topics relating to 
cervical cancer and HPV: cervical cancer being caused by HPV 
infection, HPV being acquired from sexual relations, the num-
ber of cervical cancer cases that have been increasing in women 
in their 20s, how cervical cancer has an effect on fertility, and 
how she may lose her life due to cervical cancer. We found no 
significant differences in the answers given by the girls in the 
two groups (Table 3).
However, in reference to a question about having conversa-
tions with family members about cervical cancer, of 251 
responses from the vaccination-recommended group, 44.6% 
Table 1. Characteristics of the internet survey responders.
Responder Characteristics
Subjects Recommended Suspended p-value
Resident area 251 184 n.s.
Hokkaido 15 (6.0%) 7 (3.8%)
Touhoku 15 (6.0%) 10 (5.4%)
Kantou 81 (32.3%) 69 (37.5%)
Chubu 45 (17.9%) 27 (14.7%)
Kinki 54 (21.5%) 35 (19.0%)
Chugoku 13 (5.2%) 12 (6.5%)
Shikoku 4 (1.6%) 2 (1.1%)
Kyushu/Okinawa 24 (9.5%) 22 (12.0%)
Civil status <0.001
Unmarried 227 (90.4%) 182 (98.9%)
Married 24 (9.6%) 2 (1.1%)
Employment status 0.005
Company employee (others) 4 (1.6%) 2 (1.1%)
Stay-at-home 24 (9.6%) 2 (1.1%)
Part-time staff 10 (4.0%) 9 (4.9%)
Student 208 (82.8%) 164 (89.1%)
Other 5 (2.0%) 7 (3.8%)
Household income n.s.
<2 million yen 31 (12.3%) 16 (8.7%)
2–4 million yen 24 (9.5%) 8 (4.3%)
4–6 million yen 13 (5.2%) 7 (3.8%)
6–8 million yen 10 (4.0%) 8 (4.3%)
8–10 million yen 6 (2.4%) 8 (4.3%)
>10 million yen 3 (1.2%) 7 (3.8%)
Unknown 89 (35.5%) 59 (32.1%)
NA 75 (29.9%) 71 (38.7%)
Table 2. Recognition of HPV vaccine.
Yes Maybe No
Do you know HPV vaccine?
Recommended 248 (98.8%) 3 (1.2%)
Suspended 111 (60.3%) 73 (39.7%)
p < .001
Do you know the best timing of HPV vaccination was before having first sexual 
relationship?
Recommended 47 (18.7%) 33 (13.1%) 171 (68.2%)
Suspended 13 (7.1%) 30 (16.3%) 141 (76.6%)
p = .002
Do you know the preventive effect for cervical cancer?
Recommended 26 (10.4%) 69 (27.5%) 156 (62.1%)
Suspended 19 (10.3%) 46 (25.0%) 119 (64.7%)
p = .66
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had talked with their families, 43.8% had not, and 11.6% did 
not remember. In the recommendation-suspended group, only 
25.0% had talked with their families about cervical cancer, 
64.1% did not, and 10.9% did not remember. The girls in the 
vaccination-recommended group were much more likely to 
have talked with their families about cervical cancer 
(p < .0001) (Table 4).
When asked if they worried about acquiring cervical cancer, 
in the vaccination-recommended group, 32.7% worried a lot, 
41.8% worried somewhat, 19.9% worried only a little, and 5.6% 
did not worry at all. In the recommendation-suspended group, 
9.7% worried a lot, 46.2% worried somewhat, 37.0% worried 
a little, and 7.1% did not worry at all. The girls in the vaccina-
tion-recommended group worried more about acquiring cervi-
cal cancer (p < .0001) (Table 4).
In reference to the question about feeling resistant toward 
talking about cervical cancer with her friends and acquain-
tances, in the vaccination-recommended group 29.9% said 
they felt resistant, 23.9% said they did not feel resistant, and 
46.2% were unsure if they were hesitant. In the 
recommendation-suspended group, 34.2% felt resistant, 23.9% 
did not feel resistant, and 33.7% were unsure. The girls in the 
recommendation-suspended group were more likely to feel 
resistance (34.2% vs 29.9%) toward talking about cervical can-
cer with their friends and acquaintances (p = .0262) (Table 4).
Cervical cancer screening
In reference to having cervical cancer screening, in the vacci-
nation-recommended group, 1% (2 women) had a regularly 
scheduled screening, 11.6% had been several times, and 
87.4% had never been screened. In the recommendation- 
suspended group, 1.1% (2 women) had screenings on 
a regular schedule, 3.8% had been screened several times, and 
95.1% had never been screened. The girls growing up in the 
vaccination-recommended group had cervical screenings more 
often than the girls in the recommendation-suspended group 
(p = .014). (Table 5).
Discussion
In the recommendation-suspended group, 39.7% of the girls 
answered they had never heard of the HPV vaccine. They 
learned about HPV vaccine in this survey and asked her 
mother about HPV vaccine and her own vaccine status to 
answer our questions. On the other hand, 98.8% of the girls 
in the vaccination-recommended group had heard of the HPV 
vaccine. The girls in the vaccination-recommended group were 
significantly more aware of the HPV vaccine than the girls in 
the recommendation-suspended group, even though none of the 
girls in either group were HPV-vaccinated. The girls in the 
vaccination-recommended group were also more cognizant that 
the best timing for HPV vaccination was before having first her 
sexual relationship. However, more than 60% of the girls in the 
vaccination-recommended group did not know very much 
about the specific preventative effect of the HPV vaccine for 
cervical cancer. We assumed that the reason for this knowledge 
gap was that they either were never told, forgot, or they did not 
fully understand the concept of cervical cancer at age 12–16 
when their family talked to them about getting the HPV 
vaccine.
We did not find a significant difference for knowledge 
about cervical cancer between girls in the two groups. The 
girls in the vaccination-recommended group had talked more 
about cervical cancer with their families and they felt less 
hesitant in talking about cervical cancer with their friends 
and acquaintances, and they were more concerned about 
getting cervical cancer than the girls in the recommendation- 
suspended group (Table 4). We presume that the increased 
concern was the result of conversations with the family that 
gave them more accurate knowledge about cervical cancer, 
Table 3. Knowledge of cervical cancer.
Yes Maybe No
Do you know that cervical cancer is caused by HPV?
Recommended 26 (10.4%) 39 (15.5%) 186 (74.1%)
Suspended 16 (8.7%) 38 (20.6%) 130 (70.7%)
p = .3593
Do you know that HPV is acquired from sexual relations?
Recommended 38 (15.2%) 51 (20.3%) 162 (64.5%)
Suspended 24 (13.0%) 35 (19.0%) 125 (68.0%)
p = .7398
Do you know that cervical cancer cases are increasing for women in their 20s?
Recommended 46 (18.3%) 79 (31.5%) 126 (50.2%)
Suspended 30 (16.3%) 67 (36.4%) 87 (47.3%)
p = .5475
Do you know that cervical cancer has an effect on your fertility?
Recommended 121 (48.2%) 77 (30.7%) 53 (21.1%)
Suspended 98 (53.3%) 47 (25.5%) 39 (21.2%)
p = .4675
Do you know you may lose your life from cervical cancer?
Recommended 79 (31.5%) 80 (31.9%) 92 (36.6%)
Suspended 65 (35.3%) 54 (29.4%) 65 (35.3%)
p = .6882
Table 4. Perceptions about cervical cancer.
Yes No Unknown
Did you ever talk with your family about cervical cancer?
Recommended 112 (44.6%)110 (43.8%) 29 (11.6%)
Suspended 46 (25.0%) 118 (64.1%) 20 (10.9%)
p < .001
How worried are you about acquiring cervical cancer?
Very much Somewhat A little Not at all
Recommended 82 (32.7%) 105 (41.8%)50 (19.9%)14 (5.6%)
Suspended 18 (9.8%) 85 (46.2%) 68 (37.0%)13 (7.0%)
p < .001
Do you feel resistance in talking about cervical cancer?
Yes No Unknown
Recommended 75 (29.9%) 60 (23.9%) 116 (46.2%)
Suspended 63 (34.2%) 59 (23.9%) 62 (33.7%)
p = .026
Table 5. Cervical cancer screening.
Regularly Several times Never
Have you ever had cervical cancer screening?
Recommended 2 (0.8%) 29 (11.6%) 220 (87.6%)
Suspended 2 (1.1%) 7 (3.8%) 175 (95.1%)
p = .015
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allowing them to recognize that cervical cancer is a real dis-
ease threat, and a far more common disease than they might 
have expected. Hence, they worried more about acquiring the 
disease. This group also felt less resistance to talking about 
cervical cancer with friends and acquaintances, perhaps 
a benefit of the accurate information gained through talking 
with family. On the other hand, the girls in the recommenda-
tion-suspended group did not recognize the risk of cervical 
cancer well. They felt hesitant in talking about cervical cancer 
with friends and acquaintances, perhaps because they know 
that cervical cancer was related to having sexual relations and 
were embarrassed to admit they were engaging in sex. The 
girls in the recommendation-suspended group did not worry as 
much about getting cervical cancer, perhaps living up to the 
old motto: Ignorance is bliss.
Not only governmental recommendation but also the news 
about adverse events was possible to be a background factor. The 
news about adverse events after HPV vaccination was more often 
reported in 2015 than in 2020. The girls who responded in 2015 
should have heard about the news more than the girls who 
responded in 2020. The girls who had heard of the news could 
ask her family about HPV vaccine and cervical cancer.
Significantly more girls in the vaccination-recommended group 
than in the recommendation-suspended group already had cervical 
cancer screenings at the time of our survey of the 19–20 year olds. 
Screening is expected to be almost as powerful a preventative 
measure against cervical cancer as the HPV vaccine itself. It has 
been reported that the cervical cancer screening rate is higher 
among U.S. women who received the HPV vaccine than unvacci-
nated women, 3 but here we are analyzing two groups of women, 
who were never vaccinated, for their thinking. We assume that the 
reason for the higher screening levels for the unvaccinated women 
who came of age for HPV-vaccination during the pro-vaccine 
years was the result of them at least talking about the vaccine and 
cervical cancer with their families – even though they did not get 
vaccinated for whatever reason at the time – and these conversa-
tions at least made the girls and their mothers more aware of the 
disease, increasing the likelihood of the daughter later developing 
the good habit of routinely visiting a gynecologic clinic.
In a previous study, we explored the cervical cancer screening 
rates among HPV-vaccinated and unvaccinated Japanese women. 
The cervical cancer screening rate among HPV-vaccinated 
women at age 20 was 6.4%, the rate for unvaccinated women 
was 3.9%.10 However, in this current study, we are comparing 
only unvaccinated to other unvaccinated women. The women in 
both surveys were all 18–19 years old when surveyed, but the 
surveys were taken years apart. The one group of unvaccinated 
women, the vaccination-recommended group, were teenagers 
through a time when the government, and society in general, 
was proactive toward HPV vaccination. The second group were 
teenagers during a time of anti-vaccine paranoia. There was 
a significant positive difference in the first group’s knowledge 
about the HPV vaccine and cervical cancer, and in their cancer 
screening rates. This was a remarkable outcome because the only 
major difference between the two groups of unvaccinated women 
was that, when they were teenagers, the local government was, or 
was not, actively recommending HPV vaccination.
Under normal circumstances, all women should have 
a routine of thorough cancer screening. It has been suggested 
that the cervical cancer screening rate would be lower in the 
recommendation-suspended group of girls. We have shown here 
that the adverse effects from 7 years of suspending HPV vacci-
nation have also clearly included reducing the preventive 
effects of cervical cancer screening. These deficiencies will 
have important future consequences for preventing cancer in 
Japanese women.
We theorize that one problem with the suspension of the 
government’s recommendation for the HPV vaccination is that 
it precludes one of the good chances a young girl might have for 
talking about the HPV vaccine, cervical cancer, and future cervical 
cancer screening with her family. Because the HPV vaccine is no 
longer state-recommended, Japanese mothers now seldom talk to 
their teenage daughters about HPV vaccination or about cervical 
cancer. Sex education classes in Japan are a little better. However, 
if HPV vaccination becomes once again recommended by our 
government, most mothers would be much more likely to con-
sider HPV vaccination for their daughters and they would try to 
talk about it with their daughters. Mothers would learn more 
about the HPV vaccine and cervical cancer, they would involve 
their husbands more in the decision-making process, they would 
give their daughters more accurate information about the HPV 
vaccine, cervical cancer, and sexual education. Their daughters 
would improve their understanding of the HPV vaccine and 
cervical cancer through these conversations, would think of the 
disease as a real threat, and they would learn to fear the disease 
enough to try harder to prevent the acquiring of it.
Mothers in Japan play a pivotal role in their daughters’ 
vaccination decision-making. In our previous study, we 
found that, under the hypothetical scenario of a restart of the 
government’s recommendation for the vaccine, the percentage 
of mothers who would be thereafter willing to encourage their 
daughters to get the HPV vaccine increased significantly, from 
12.1% to 21.0% (p < .001). Educating mothers about the HPV 
vaccine and about HPV-caused cancers positively changed 
their attitude toward the HPV vaccine and raised the rate of 
likely vaccination encouragement to 27.3%.11
We also previously found that the father’s participation in 
the family decision-making concerning vaccination was signif-
icantly associated with increased vaccination of his daughter 
(odds ratio: 3.9, 95%CI: 2.35–6.46). When the father had 
a positive attitude toward HPV vaccination, the relationship 
between the father’s participation in decision-making and their 
daughter’s inoculation was even more enhanced (odds ratio: 
10.51, 95%CI: 5.16–21.62) (Shindo et al. submitted).
Mothers also play a significant role in their daughters’ cervical 
cancer screening decision-making. In our previous study, 20-year- 
old girls who had not yet received their first cervical cancer 
screening were randomized into two study groups. One group 
received only a personalized daughter-directed reminder leaflet 
for cervical cancer screening. In the second group, both the 
daughters and their mothers received a combination package 
containing the same reminder leaflet as did the first group, plus 
an additional informational leaflet for the mother, which 
requested that the mother recommends that her daughter under-
goes cervical cancer screening. The cervical cancer screening rate 
of 20-year-old women whose mothers received an information 
leaflet was significantly higher than that for women who received 
only a leaflet for themselves (11% vs 9%, p = .0049).12
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Considering the above, talking about the HPV vaccine and 
cervical cancer with their families is very important for promoting 
HPV vaccination and cervical cancer screening. But the suspen-
sion of the government’s recommendation for the HPV vaccina-
tion program has removed one of the best opportunities for 
families to have these discussions. Hence, we think the govern-
mental recommendation should be resumed as soon as possible.
Our study has some limitations. Firstly, there were more 
married women in the vaccination-recommended group than 
the girls in the recommendation-suspended group. The married 
girls could have more chances to have cervical cancer screening 
before they had gotten married although our survey revealed 
that the girls growing up in the vaccination-recommended 
group had cervical screenings more often than the girls in the 
recommendation-suspended group. Secondly, we selected 
18–19 year-old girls for our survey, although the recommended 
age to begin cervical cancer screening is 20 and up in Japan. 
Hence, when they become 20-year-olds and receive their cer-
vical cancer screening reminder leaflet, it is unclear whether 
they actually attend a cancer screening. The actual recognition 
regarding cervical cancer and the actual cancer screening rate 
may not correlate with the rate found in this investigation. 
However, these girls will soon be 20, and we expect that it 
will be possible for us to recommend cancer screening to them 
in better ways, based on the knowledge and information 
obtained in this investigation.
Conclusions
The girls in the vaccination-recommended group know more 
about the HPV vaccine and cervical cancer and had cervical 
cancer screening more often than the girls in the recommenda-
tion-suspended group. Talking about the HPV vaccine and cervical 
cancer with their families is a critical means for promoting HPV 
vaccination and cervical cancer screening. But the continued 
suspension of the government’s recommendation for the HPV 
vaccination program steals a key opportunity for young girls of 
recommendation age talking about these matters with their 
family.
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